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Purpose: The corneal wound healing response to an alkali burn results in dysregulated inflammation and opacity. Transient
receptor potential vanilloid type1 (TRPV1) ion channel activation by such a stress contributes to this unfavorable outcome.
Accordingly, we sought to identify potential drug targets for mitigating this response, in human corneal epithelial cells
(HCEC).
Methods: SV40-immmortalized HCEC were transduced with lentiviral vectors to establish stable c-Jun N-terminal
kinase1  (JNK1),  nuclear  factor-κB1  (NF-κB1),  and  dual  specificity  phsophatase1  (DUSP1)  shRNAmir  sublines.
Immunoblotting evaluated the expression of NF-κB1, DUSP1, protein kinase Cδ (PKCδ), and the phosphorylation status
of  cell  signaling  mediators.  Enzyme-linked  immunosorbent  assay  (ELISA)  evaluated  interleukin-6  (IL-6)  and
interleukin-8 (IL-8) release.
Results: Capsaicin (CAP; a selective TRPV1 agonist), induced time-dependent activation of transforming growth factor-
activated kinase 1 (TAK1) and mitogen-activated  protein kinase (MAPK) cascades temporally followed by increased
nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IκBα) phosphorylation, rises in both
PKCδ protein levels and IL-6 and IL-8 release. All of these responses were blocked by the TAK1 inhibitor 5z-7-oxozeaenol
(5z-OX). In the JNK1 subline, CAP failed to increase IL-6/8 release, but still stimulated NF-κB by 50%. In the NF-κB1
subline, these IL-6/8 responses were absent, JNK1 activation was attenuated and there was a concomitant increase in
DUSP1 expression compared to the control. In the DUSP1 subline, JNK1 phosphorylation was enhanced and prolonged
and accompanied by larger increases in IL-6/8 release.
Conclusions: TRPV1 induced increases in IL-6/IL-8 release occur through TAK1 activation of JNK1-dependent and
JNK1-independent signaling pathways. Their joint activation is required for NF-κB to elicit sufficient positive feedback
control of JNK1/2 phosphorylation to elicit increases in IL-6/8 release. Such regulation depends on NF-κB modulation
of DUSP1 expression levels and associated changes in PKCδ protein levels.
Severe  corneal  injury  by  an  alkali  burn  leads  to
dysregulated  inflammatory  responses  and  scarring  during
wound healing. Recent studies show that transient receptor
vanilloid type1 (TRPV1) channel activation by endogenous
vanilloids and endocannabinoids may play a critical role in
this  sight-compromising  outcome  [1].  TRPV1,  originally
identified  as  the  receptor  for  the  pungent  chili  pepper
component capsaicin (CAP), acts as an integrator for noxious
thermal  and  chemical  stimuli  to  transduce  pain  and
inflammation in a host of different tissues [2,3]. Accordingly,
extensive effort is being exerted to develop TRPV1-related
therapeutic  strategies  to  mitigate  these  stress-induced
responses.
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Outcomes  of  TRPV1  activation  in  human  corneal
epithelial  cells  (HCEC)  include  enhanced  release  of
interleukin-6  (IL-6),  a  proinflammatory  agent  and
interleukin-8 (IL-8), a chemoattractant [4-6]. Identified signal
transduction  events  mediating  these  responses  include
transient  intracellular  Ca2+  rises  and  phosphorylation  of
kinases belonging to the p38, extracellular regulated kinase
(ERK)1/2  and  c-jun  terminal  kinase  (JNK)1/2  mitogen-
activated protein kinase (MAPK) cascades suggesting that all
three  MAPK  pathways  may  be  involved  in  downstream
TRPV1 effects. In the same cells, however, inflammatory
responses mediated by Toll-like receptor (TLR) have been
recently reported to depend solely on the JNK MAPK pathway
leading  to  nuclear  factor-κB  (NF ț%)Dctivation.   The
physiologic relevance of JNK activation was documented by
showing  in  JNK1−/−  (knockout)  mice  that  TLR2-induced
corneal stromal neutrophil recruitment and haze development
were  markedly  reduced  [7].  These  aforementioned  results
prompted us to examine the roles of the different MAPK
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3137Figure 1. CAP induces TAK1 activation. A: TRPV1-induced TAK1 and JNK1 phosphorylation. CAP (20 µM) in scrambled shRNA HCEC
subline caused timedependent changes in TAK1 (left) and JNK1 (right) phosphorylation as revealed by western blot analysis. TAK1 expression
level invariance validates protein loading equivalence. Results shown are representative of three independent experiments. B: Inhibition of
TAK1 phosphorylation. Preincubation of scrambled shRNA subline for 60 min with either CPZ (10 µM) or 5z-OX (0.1 µM) suppressed CAP
(20 µM)-induced TAK1 activation. TAK1 expression level invariance validates protein loading equivalence. C: Dosedependent inhibitory
effects of 5z-OX on TAK1 and MAPK phosphorylation. Scrambled shRNA subline was preincubated with 5z-OX (0.01–1.0 µM) for 1 h
before exposure to CAP (20 µM) for 5 min. JNK1/2 expression level invariance validates protein loading equivalence. D: Dependence of IL-6
and IL-8 increases on TRPV1 and TAK1 activation. ELISA was performed after 24 h in presence or absence of CAP (20 µM). Each experiment
was performed three times using triplicate samples. Results are expressed in pg/mg protein. Following 60 min exposure to CPZ (10 µM) or
5z-OX (0.1 µM), the effects of CAP (20 µM) were determined on the release of IL-6 and IL-8.
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3138pathways and other relevant proteins on IL-6/8 release when
mediated instead by TRPV1.
We show here in HCEC that: a) CAP induces cytokine
release through sequential activation of transforming growth
factor-activated kinase 1 (TAK1), JNK1 and NF-κB; b) NF-
κB  activation  is  mediated  by  TAK1  through  both  JNK1-
dependent  and  JNK1-independent  pathways;  c)  NF-κB
contributes to JNK1 activation through a positive feedback
control; d) This feedback is mediated through modulation of
dual  specific  protein  phosphatase  1  (DUSP1)  expression
levels. These findings suggest that DUSP1 and JNK1 are
novel potential drug targets for suppressing injury-induced
inflammation and scarring associated with TRPV1 activation.
METHODS
Reagents:  Capsaicin  (CAP),  capsazepine  (CPZ),  TAK1
inhibitor  5z-7-oxozeaenol  (5z-OX),  and
pyrrolidinedithiocarbamate  (PDTC)  were  purchased  from
Sigma-Aldrich  (St.  Louis,  MO). Anti-phospho-ERK,  total-
ERK, total-p38, total-JNK, and β-actin antibodies were from
Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phospho-
TAK1, phospho-p38, phospho-JNK/SAPK, phospho-nuclear
factor of kappa light polypeptide gene enhancer in B-cells
inhibitor, alpha (IκBα), total-TAK1, total-NF-κB1 and protein
kinase  Cδ  (PKCδ)  antibodies  were  purchased  from  Cell
Signaling  Technology  (Danvers, MA).   The  anti-DUSP1
antibody was obtained from ABNOVA (Walnut Creek, CA).
IL-6   and       IL-8   ELISA     kits   were  from  R&D  Systems 
(Minneapolis, MN).
Cell  culture:  SV40  adenovirus-immortalized  HCEC,  a
generous  gift  from  Araki-Sasaki  (Kagoshima  Miyata  Eye
Clinic, Kagoshima, Japan), were cultured at 37 °C in the
presence of 5% CO2, 95% atmosphere air in a humidiﬁed
incubator  with  1:1  mix  of  Dulbecco’s  modiﬁed  Eagle’s
medium and Ham F12 (DMEM/F12) supplemented with 10%
fetal bovine serum (FBS), 5 ng/ml EGF, 5 μg/ml insulin, and
40 μg/ml gentamicin. CAP-induced responses were elicited
subsequent to overnight serum starvation in growth factor-
free medium.
Lentiviral vectors: Lentiviral vectors for stable expression of
shRNAmir sequences against DUSP1, JNK1, and NF-κB1
were generated using pGIPz plasmid clones V3LHS_352110,
V2LHS_61931,  and  V3LHS_170502,  respectively  (Open
Biosystems, Hunstville, AL). Blast analysis of the 20-mer
antisense sequences expressed by these clones demonstrated
that in each case only the intended target RNA was a full
sequence match. The expression cassette incorporated into the
host cell DNA by these lentiviral vectors drives the expression
of  a  turbo-GFP  protein,  the  shRNAmir  sequence  and  a
puromycin selection gene from a single CMV promoter. Viral
particles  were  generated  by  transducing  HEK293T  cells
cultured in 100-mm dishes with 2 μg active plasmid and 8 μg
of packing plasmid mix (Biogenova UMIX™; Potomac, MD)
in 10 ml medium (DMEM with 10% FBS) containing 20 μl
HEKFectin (BioRad, Richmond, CA). The culture medium
was  refreshed  after  overnight  incubation  and  virus-rich
supernatant was collected 48 h later after confirming that most
HEK293  cells  developed  strong  GFP  fluorescence.
Transduced cells were selected with puromycin (5 μg/ml)
using  the  disappearance  of  all  GFP-negative  cells  and
elimination of all cells from an untransduced control culture
as selection end points. To generate a control subline for
evaluating  any  non-specific  effects  of  shRNAmirs,  viral
particles  incorporated  a  cassette  for  the  simultaneous
expression  of  a  non-coding  shRNAmir  and  puromycin
resistance. After puromycin selection, these cells were used
to determine if transfection had non-specific effects on cell-
line functional properties.
Western  blot  analysis:  After  HCEC  reached  about  80%
confluence, they were gently washed twice in cold phosphate-
buffered saline (PBS) and harvested in 0.5 ml cell lysis buffer
containing 20 mM Tris, 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate,
1 mM β-glycerol phosphate, and 1 mM Na3VO4, pH 7.5, with
a  protease  inhibitor  mixture  (1  mM  PMSF,  1  mM
benzamidine, 10 μg/ml leupeptin, and 10 μg/ml aprotinin).
Cells were scraped with a rubber policeman, followed by
sonication and centrifugation (10,000× g for 15 min at 4 °C).
The protein concentration of each lysate was determined by
bicinchoninic acid assay (micro BCA protein assay kit; Pierce
Biotechnology, Rockford, IL). After boiling samples for 5
min, 20–50 μg denatured protein was electrophoresed in 10%
polyacrylamide  sodium  dodecylsulphate  (SDS)  minigels,
followed by electrophoresis and blotted onto an Immun-Blot
PVDF  membranes  (Bio-Rad,  Hercules,  CA).  Membranes
were blocked with blocking buffer, 5% fat-free milk in 1×
PBS  buffer-0.1%  Tween-20  for  1  h  at  room  temperature
reacted overnight at 4 °C and probed with primary antibodies
of interest. Membranes were incubated with 1:2,000 dilution
of a secondary antibody with goat anti-rabbit or mouse IgG
for 1 h at room temperature. Immunobound antibody was
visualized using an enhanced chemiluminescence detection
system ECL Plus (GE Healthcare, Piscataway, NJ). Images
were  analyzed  by  densitometry  (SigmaScan  Pro  Mountin
View, CA). All experiments were repeated at least three times
unless otherwise indicated.
Enzyme-linked  immunosorbent  assay  (ELISA):  ELISA  for
IL-6 and IL-8 was performed according to the manufacturer’s
instructions. The amount of IL-6 or IL-8 in the culture medium
was  normalized  to  total  amount  of  protein  obtained  by
dissolving the washed cells in 2% SDS and 0.5 N NaOH. Each
experiment was performed in triplicate with three replicates.
Data  analysis:  All  results  are  reported  as  means±SEM.
Statistical  significance  was  assessed  using  the  using  non-
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3139paired Students t-test. They were considered significant if
p<0.05.
RESULTS
TRPV1-induces  IL-6/8  release  through  TAK1  and  MAPK
phosphorylation: In Figure 1A (left and right panels), the time
dependent  effects  in  the  scrambled  shRNA  subline  are
compared of 20 μM CAP addition on phosphorylated-TAK1
(p-TAK1) and p-JNK1 formation. With TAK1, its activation
level increased by 1.3 fold after 2.5 min followed by a decline
Figure 2. Dependence of CAP-induced increases in IL-6 and IL-8
release on JNK1 activation. A: Validation of JNK1 knockdown.
Western blot analysis compares total JNK1 protein expression in
parental wildtype (WT), resting scrambled shRNA and JNK1 HCEC
subline. Expression levels in scrambled and WT HCEC were the
same. JNK1/2 expression level invariance validates protein loading
equivalence. B: Loss of JNK1 expression obviates IL-6/8 responses
to TRPV1 activation. ELISA was performed on scrambled shRNA
and JNK1 subline after 24 h in the presence or absence of CAP (20
µM).  Results  are  from  three  independent  experiments  each
performed in triplicate.
after 30 min to reach nearly a baseline value. On the other
hand, increases in JNK1 phosphorylation status occurred with
a slower course reaching after 15 min a level that was nearly
threefold  above  the  control.  Figure  1B  shows  that  either
10 μM CPZ (a TRPV1 antagonist) or 5z-OX (a selective
TAK1 inhibitor) suppressed the peak rise by 90% and 100%
respectively  indicating  that  TAK1  activation  is  indeed
mediated by TRPV1. Figure 1C,D show that in addition to its
effect on TAK1, 1 μM 5z-OX fully inhibited CAP induced
phosphorylations of all three MAPK terminal kinases and
blocked  the  CAP-induced  rises  in  IL-6  and  IL-8  release
without suppressing baseline levels of IL-6/8 release. CPZ
also did not affect changes in their baseline values showing
that this antagonist was not cytotoxic.
TRPV1-induced IL-6/8 release requires activation of both
JNK1 and NF-κB: The role of JNK1 activation in mediating
CAP-induced increases in IL-6/8 was determined in the JNK1
subline. JNK1 protein levels in this subline were reduced by
more than 90% (Figure 2A) relative to the scrambled shRNA
cell line and were indistinguishable from those in the parent
HCEC. The  drastic decrease in JNK1 expression abolished
CAP-induced  increases  in  IL-6/8  release  (Figure  2B)
demonstrating the central role of JNK1 activity in driving
these  responses.  The  selectivity  of  the  shRNA  design  in
suppressing JNK1 expression was previously validated by
showing  in  the  JNK1  shRNA  subline  that  the  mitogenic
response to EGF was enhanced relative to that in scrambled
cells [8].
A  NF-κB1  subline  assessed  NF-κB  involvement  in
eliciting CAP-induced IL-6/8 release. Figure 3A shows that
the knockdown was nearly complete. As CAP failed to cause
any increases in IL-6 /8 release in this subline, this negative
effect demonstrates the essential role of this inflammation
mediator in the TRPV1 response (c.f. Figure 3B [left and
right]).
TAK1 and JNK1 activities are essential for NF-κB activation:
To  determine  whether  NF-κB  activation  by  TRPV1  is
dependent on TAK1 and/or JNK1 activity, as was described
for some other different receptors in other tissues [9,10], we
monitored the phosphorylation status of IκBα, a protein that
when  unphosphorylated  binds  to  NF-κB  and
stoichiometrically inhibits its activity [11]. Figure 4A shows
that upon addition of CAP increases in p-IκBα formation
reached after about 60 min a maximal value, which was slower
than the rises in p-TAK1 expression (Figure 1A). In the JNK1
subline, relative to the scrambled subline, this CAP-induced
IκBα phosphorylation was reduced only by 50%; 0.1 µM 5z-
OX eliminated the remaining 50% of this response (Figure
4B) suggesting that TAK1 may also activate NF-κB through
a JNK1-independent pathway.
NF-κB activity modulates JNK1 phosphorylation status via a
positive  feedback  loop  involving  DUSP1  and  PKCδ:  In
addition to the dependence of NF-κB activation on JNK1
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3140phosphorylation, in several other cell systems, NF-κB has
been shown to increase the duration and magnitude of JNK1
phosphorylation through positive feedback control [12]. To
assess the functionality of this effect in HCEC, we compared
the  time-dependent  effects  of  CAP  on  terminal  kinase
phosphorylation in scrambled shRNA cells with those in the
NF-κB1  subline  (Figure  4C).  In  both  cases,  peak
phosphorylation responses were observed at about 15 min, but
the responses in this subline were diminished, suggesting that
the feedback mechanism is operative. Figure 4C also indicates
that similar suppression patterns were observed in p-ERK1/2
and  p-p38  formation.  These  global  declines  in  MAPK
terminal kinase phosphorylation levels in the absence of NF-
κB1 expression led us to focus attention on DUSP1, a dual
specificity  phosphatase,  which  is  highly  expressed  in  the
HCEC and displays similar high affinity for all three MAPK
terminal kinases [13,14]. Figure 4D shows that at 90 min post
TRPV1 activation, DUSP1 expression in the NF-κB1 subline
was still nearly threefold higher than that in the scrambled
shRNA control cells.
Additionally, noting that in murine embryonic fibroblasts
and in neurons loss of NF-κB activity has been linked to
declines in PKCδ expression and rises in DUSP1 expression
[15,16], we hypothesized that such a relationship also exists
in HCEC. Comparative measurement of CAP on DUSP1 and
PKCδ expression in the scrambled shRNA subline and NF-
κB1 subline confirmed this assumption. In the control system,
the results shown in Figure 4D indicate that CAP caused a
nearly threefold increase in PKCδ expression whereas DUSP1
remained essentially invariant. Conversely, in the NF-κB1
subline, PKCδ remained invariant and low whereas DUSP1
expression rose rapidly by more than fourfold after 15 min.
DUSP1 modulates TRPV1-induced IL-6/8 release through
control of JNK phosphorylation: To assess the contribution
by DUSP1 in mediating NF-κB control of JNK1 activation,
CAP-induced MAPK TK activation patterns were evaluated
in  a  DUSP1  subline  displaying  an  85%  reduction  in
phosphatase expression (Figure 5A). Figure 5B shows that in
the scrambled shRNA cells terminal kinase phosphorylation
rapidly reached a peak within 15 min, which gradually waned
during the next 60 min. On the other hand, in the DUSP1
subline, terminal kinase activation underwent larger increases
at the beginning and remained invariant for a longer period
particularly in the case of JNK1/2. Figure 5C shows the impact
of enhanced and prolonged JNK1 phosphorylation on IL-6/8
release. After 24 h exposure to CAP, IL-6/8 release was 1.4
fold and 2.6 fold more, respectively, in the DUSP1 subline
than in the scrambled cells.
DISCUSSION
We  show  here  that  TRPV1  mediates  NF-κB  activation
through  a   JNK1-dependent  and  JNK1-independent  path-
ways.  Stimulation  of  both  pathways  is  mediated  through
CAP-induced  TAK1 phosphorylation.  This  type  of control
of NF-κB has been described in some other tissues [9,10,17].
JNK1 in the MAPK  cascade is  the only mediator of IL-6/8
release since CAP  failed to induce  this response in the JNK1
shRNA     HCEC     subline     (Figure 2B).       LR2-induced
IL-release  is  also  solely  dependent   on  JNK1  activation
−/− because   in   JNK1    knockout   mice  and  in HCEC drug
blockade of JNK activation inhibited this response [7].
Figure  3.  Dependence  of  TRPV1-
induced increases in IL-6/8 release on
NF-κB  activation.  A:  NF-κB1/p50
protein expression levels in parental WT
cells,  scrambled  shRNA  and  NF-κB
sublines were compared by western blot
analysis.  Glyceraldehyde-3-phosphate
dehydrogenase  (GAPDH)  expression
level  invariance  validates  protein
loading  equivalence.  B:  CAP  fails  to
induce IL-6 and IL-8 rises in NF-κB1
subline. ELISA was performed after 24
h in the presence or absence of CAP (20
µM)  for  both  scrambled  shRNA  and
JNK1 sublines. Results are from three
independent  experiments  each
performed in triplicate.
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3141Figure 4. Positive feedback control of JNK1 phosphorylation by NF-κB through DUSP1. A: Timedependent increases in p- IκBα. Scrambled
shRNA subline was exposed to CAP (20 µM) for up to 90 min. Western blots reveal the time course of changes in p-IκBα formation, which
serves as a readout of NF-κB activation. B: Contribution by JNK1 to IκBα phosphorylation. Western blots compare CAP (20 µM)induced
IκBα phosphorylation in scrambled shRNA and JNK1 sublines at 60 min. Preincubation with either 5z-OX (0.1 µM), CPZ (10 µM) or PDTC
(50 µM) for 60 min suppressed CAP-induced IκBα phosphorylation. C: Positive feedback control by NF-κB of JNK1/2 activation. Loss of
NF-κB activation reduces transient JNK1/2, p38, and ERK1/2 MAPK activation induced by CAP (20 µM) for up to 90 min. Summary plots
contrast timedependent patterns of MAPK activation in the scrambled shRNA subline (left) with those in NF-κB1 subline (right). D: Inverse
relationship between changes in PKCδ and DUSP1 expression. Scrambled shRNA and NF-κB1 sublines were exposed to CAP (20 µM) as
described in B. Summary plot (left) indicates that in the scrambled shRNA subline CAP-induced increases in PKCδ expression whereas
DUSP1 remained invariant (left). Summary plot (right) reveals inverse responses by PKCδ and DUSP1 to CAP in NF-κB1 subline.
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3142Figure 5. Changes in MAPK activation patterns and IL-6/8 release in DUSP1 subline. A: Western blot analysis of  total DUSP1 Protein
expression in resting scrambled HCEC and DUSP1 subline. B: Comparison of time dependent changes in MAPK phosphorylation in scrambled
shRNA and DUSP1subline. Cells were exposed to CAP (20 µM) for indicated times. Changes are compared in p-ERK1/2, p-JNK1/2, and
p38 MAPK in two different sublines. Protein loading equivalence validated based on invariant ERK1/2 expression levels. C: DUSP1 gene
knockdown enhances CAP-induced IL-6 and IL-8 release. ELISA was performed on scrambled shRNA and DUSP1 subline after 24 h exposure
to CAP (20 µM). Three independent experiments each performed in triplicate.
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3143One of the roles of JNK1 in mediating IL-6/8 release is
to  activate  NF-κB,  a  downstream  essential  player  in  this
secretory  process.  Interleukin  release  is  further  helped  or
reinforced by the presence of a positive feedback loop in
which  NF-κB,  fosters  stabilization  and/or  prolongation  of
JNK1 phosphorylation since in the NF-κB1 subline CAP-
induced JNK1 phosphorylation was attenuated (Figure 4C).
This  NF-κB  to  JNK1  positive  feedback  loop  is  clearly
mediated by inhibition of DUSP1 activity since in the DUSP1
subline JNK1 activation was enhanced and prolonged (Figure
5B). Such suppression by NF-κB of DUSP1 expression could
be dependent on NF-κB-induced increases in PKCδ protein
levels.  Similar  NF-κB-mediated changes in DUSP1 and
PKCδ expression levels have been described in embryonic
fibroblasts  and  neurons  [15,16]  whereas  in  enterocytes,
increases in NF-κB activation had a corresponding rather than
an opposite effect on LPS-induced DUSP1 expression [18].
Thus,  the  molecular  events  connecting  these  coordinated
changes and their cause and effect relationship remain to be
elucidated  and  require  independent  definition  in  each
particular system. Another remaining question is why only
combined activation by CAP of the JNK1-independent and
JNK1-dependent  pathways  is  sufficient  to  induce  IL-6/8
release. One possibility is that CAP-induced IL-6/8 release
depends on c-Jun/AP-1 and NF-κB activation, which can only
occur if JNK1 is sufficiently phosphorylated as a consequence
Figure 6. TRPV1-linked signaling pathways mediating IL-6 and IL-8 release. TRPV1 stimulation leads to TAK1-dependent JNK1 and NF-
κB activation. Activated JNK1 potentiates NF-κB activation by TAK1. NF-κB provides a positive feedback control of JNK1 phosphorylation
through inhibition of DUSP1 expression, which is possibly controlled by PKCδ. Activated NF-κB translocates to nucleus, along with other
transcription factors activated by p-JNK1 (e.g., AP-1) to promote IL-6 and IL-8 mRNA expression. Solid line indicates established interaction.
Broken line represents unproven interaction. Arrowhead means stimulation whereas hammerhead represents inhibition. Arrow pointing from
TAK1 to NF-κB is broken since it is not yet known if interaction is direct or there are signaling intermediates mediating NF-κB activation by
TAK1.
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3144of NF-κB mediated suppression of DUSP1 expression. This
is tenable since AP-1 activation can occur in 15 min after
exposing HCEC to a hyperosmotic stress, which is within the
same time frame in which JNK1 and NF-κB activation occur
(Figure 1A and Figure 4A) [19]. Our findings in the HCEC
are schematically summarized in Figure 6. These findings
have potential clinical relevance in identifying novel drug
targets  to  reduce  inflammation  and  pain  resulting  from
exposure  to  environmental  stresses  activating  TRPV1.
Strategies to suppress JNK1 activation are one possibility
since  TRPV1-induced  increases  in  IL-6/8  release  were
obviated without compromising the mitogenic response to
TRPV1 activation [8]. Another alternative is to overexpress
DUSP1 protein levels, which could lead to suppression of
JNK1  activation  and  declines  in  IL-6/8 release. This
possibility  is  consistent  with  the  finding  that  the  anti-
inflammatory effects of glucocorticoids are attributable to
DUSP1 upregulation [20]. Direct DUSP1 drug targeting could
prove to be advantageous to prolonged glucocorticoid usage
which can have several ocular side effects.
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